WO2003038047A3 - Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen - Google Patents

Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen Download PDF

Info

Publication number
WO2003038047A3
WO2003038047A3 PCT/US2002/034588 US0234588W WO03038047A3 WO 2003038047 A3 WO2003038047 A3 WO 2003038047A3 US 0234588 W US0234588 W US 0234588W WO 03038047 A3 WO03038047 A3 WO 03038047A3
Authority
WO
WIPO (PCT)
Prior art keywords
class
reverse transcriptase
associated antigen
human telomerase
telomerase reverse
Prior art date
Application number
PCT/US2002/034588
Other languages
French (fr)
Other versions
WO2003038047A2 (en
Inventor
Si-Yi Chen
Roland Schroers
Original Assignee
Baylor College Medicine
Si-Yi Chen
Roland Schroers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine, Si-Yi Chen, Roland Schroers filed Critical Baylor College Medicine
Priority to AU2002363231A priority Critical patent/AU2002363231A1/en
Publication of WO2003038047A2 publication Critical patent/WO2003038047A2/en
Publication of WO2003038047A3 publication Critical patent/WO2003038047A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464457—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to the identification of MHC-II hTRT restricted epitopes and the use of these identified epitopes to elicit an immune response against the epitope. More particularly, the identified epitopes are administered to a subject to treat hyperproliferative diseases.
PCT/US2002/034588 2001-10-29 2002-10-29 Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen WO2003038047A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002363231A AU2002363231A1 (en) 2001-10-29 2002-10-29 Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34501201P 2001-10-29 2001-10-29
US60/345,012 2001-10-29

Publications (2)

Publication Number Publication Date
WO2003038047A2 WO2003038047A2 (en) 2003-05-08
WO2003038047A3 true WO2003038047A3 (en) 2004-11-25

Family

ID=23353093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/034588 WO2003038047A2 (en) 2001-10-29 2002-10-29 Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen

Country Status (3)

Country Link
US (1) US20030143228A1 (en)
AU (1) AU2002363231A1 (en)
WO (1) WO2003038047A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
DE69723531T3 (en) 1996-10-01 2012-09-06 Geron Corp. Catalytic subunit of human telomerase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US20060073123A1 (en) * 2002-04-30 2006-04-06 Jie Mi Adenovirus vectors for immunotherapy
AU2003249357A1 (en) * 2002-06-27 2004-01-19 Geron Corporation Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase
WO2007030820A2 (en) * 2005-09-09 2007-03-15 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
TW200906435A (en) * 2007-08-14 2009-02-16 Asia Pacific Biotech Developing Inc Special short-chain peptide cancer therapeutical agent and therapeutical method thereof
PT2310044T (en) * 2008-06-16 2016-11-18 Mediolanum Farm S P A Anti-tumor immunotherapy
ES2342754B1 (en) * 2008-10-03 2011-05-11 Lipotec, S.A. USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN, MUCOSES, LEATHER AND / OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
RS59462B1 (en) 2010-02-16 2019-11-29 Ultimovacs As Polypeptides
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
JP6262722B2 (en) 2012-05-11 2018-01-17 ジェムバックス アンド カエル カンパニー，リミティド Composition for preventing or treating rheumatoid arthritis
CN104507961B (en) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 Anti-inflammatory peptide and composition comprising it
EP2873678A4 (en) 2012-07-11 2016-05-18 Gemvax & Kael Co Ltd Cell-penetrating peptide, conjugate comprising same and composition comprising same
CN104768967B (en) * 2012-09-19 2019-02-15 珍白斯凯尔有限公司 Cell permeable peptide, the conjugate comprising the peptide and the composition comprising the conjugate
KR102201429B1 (en) 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EP3449936A1 (en) 2013-03-28 2019-03-06 Invectys A cancer vaccine for cats
DK2978444T3 (en) 2013-03-28 2019-03-18 Invectys CANCERVACCINE FOR DOGS
JP6474786B2 (en) 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー，リミティド Composition for treatment and prevention of ischemic injury
BR112015030627A2 (en) 2013-06-07 2017-07-25 Gemvax & Kael Co Ltd Useful biological markers in cancer immunotherapy
KR20160039152A (en) 2013-06-21 2016-04-08 주식회사 젬백스앤카엘 Hormone secretion regulator, composition containing same, and method for controlling hormone secretion using same
CN105531284B (en) * 2013-07-12 2021-03-23 珍白斯凯尔有限公司 Cell penetrating peptides and conjugates comprising the same
ES2753412T3 (en) 2013-10-28 2020-04-08 Invectys Gene electrotransfer to skin cells
SI3062824T1 (en) 2013-10-28 2020-04-30 Invectys A telomerase encoding dna vaccine
KR102307567B1 (en) * 2013-11-12 2021-10-01 주식회사 젬백스앤카엘 Peptide having anti-inflammatory activity and composition comprising same
ES2818921T3 (en) 2013-11-22 2021-04-14 Gemvax & Kael Co Ltd Peptide having angiogenesis inhibitory activity and composition containing the same
EP3085380B1 (en) 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
KR20160102069A (en) * 2013-12-27 2016-08-26 텔로리젠, 인크. Compositions and methods for providing active telomerase to cells in vivo
JP6420459B2 (en) 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド Peptide having fibrosis inhibitory activity and composition containing the same
WO2015167067A1 (en) 2014-04-30 2015-11-05 주식회사 카엘젬백스 Composition for organ, tissue, or cell transplantation, kit, and transplantation method
KR102413243B1 (en) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 Peptides for treating ophthalmopathy and the Composition Comprising the Same
US10835582B2 (en) 2015-02-27 2020-11-17 Gemvax & Kael Co. Ltd. Peptide for preventing hearing loss, and composition comprising same
WO2017003267A1 (en) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 Peptide having anti-viral effect and composition containing same
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
CN117018162A (en) 2016-04-07 2023-11-10 珍白斯凯尔有限公司 Peptides and compositions having effects of increasing telomerase activity and extending telomeres
CN110418648B (en) * 2017-02-22 2023-09-08 丁恩雨 mRNA cancer vaccine for encoding fusion of human GM-CSF and multiple tandem epitopes
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033998A2 (en) * 1997-12-24 1999-07-08 Bayer Aktiengesellschaft Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033998A2 (en) * 1997-12-24 1999-07-08 Bayer Aktiengesellschaft Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof

Also Published As

Publication number Publication date
US20030143228A1 (en) 2003-07-31
AU2002363231A1 (en) 2003-05-12
WO2003038047A2 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
WO2003038047A3 (en) Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
WO2003028760A3 (en) Vaccine
WO2001021207A3 (en) Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
WO2006037979A3 (en) Nanoparticles comprising antigens and adjuvants and immunogenic structure
WO2002081646A3 (en) Epitope sequences
WO1999041383A8 (en) Antigen library immunization
AU4188100A (en) Dry formulation for transcutaneous immunization
DE60012042D1 (en) ENTEPNEUMOVIRUS AND APPROPRIATE VACCINE
WO2005012479A3 (en) Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
WO1999010375A3 (en) Vaccine against hpv
WO2006085983A3 (en) Viral adjuvants
EP2481422A3 (en) Multiplex vaccines
WO2006026394A3 (en) Method of eliciting an immune response against hiv
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2001058485A3 (en) Prophylactic and therapeutic antibodies against vaccina virus antigens
WO2003063899A3 (en) Vaccine adjuvant based on a cd4 0 ligand
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2006007555A3 (en) Rotavirus antigens
WO2003059385A3 (en) Hiv vaccine and method of use
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
UA87433C2 (en) Gonadotropines for stimulation of folliculogenesis
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP